MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

NCT06171685 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

NETWORK

Sponsor class

Conditions

Relapse Multiple Myeloma
Refractory Multiple Myeloma

Interventions

DRUG: Teclistamab Monotherapy
DRUG: Teclistamab

Sponsor

Multiple Myeloma Research Consortium